28 The End of Shortage Transition As of late 2024 and early 2025, the FDA began resolving the shortages of tirzepatide and semaglutide
Death occurs in up to 34% of patients with symptomatic NCM
En cambio, es probable que la llegada de los GLP-1 orales atraiga a pacientes reacios a las agujas, expandiendo el mercado total abordable (TAM) en lugar de desplazar el existente
DNMT3b modulates melanoma growth by controlling levels of mTORC2 component RICTOR
Additionally, recent studies have found that hydrochlorothiazide, as well as combination drugs, may increase the risk of certain types of skin cancer
Retatrutide carries the side-effect profile of the GLP-1/GIP class nausea, vomiting, diarrhoea, constipation plus the class-level concerns we know from Mounjaro and Wegovy: gallbladder disease, pancreatitis, kidney injury from severe dehydration, and a possible thyroid C-cell tumour signal seen in rodent studies